{"entity":{"id":"idea-reg-open-source-dossier-tools","kind":"idea","name":"Open-source dossier-building software for academic sponsors and generic makers","aka":[],"tldr":"Preparing a regulatory filing requires expensive specialist software and consultants. Free, open tools would let universities and small generic firms file in more countries.","summary":"Academic groups that run positive trials of repurposed or de-escalated regimens rarely file for label changes because eCTD authoring, publishing and validation tools are commercial and expensive. The proposal is an open-source toolchain (eCTD v4 authoring, CDISC dataset conversion, validation against regional rules, submission gateway clients) maintained by a foundation, plus templated modules for common academic filings such as new-indication supplements for off-patent drugs.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis","url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-regulatory-fragmentation","b-generic-repurposing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Within three years of release, at least ten academic or non-profit sponsors file regulatory submissions using the toolchain that they would otherwise not have made, and the cost of a multi-region generic oncology filing falls by half.","rationale":"Open-source infrastructure has repeatedly lowered barriers where the format is standardised and the buyer base is fragmented (statistics, genomics pipelines). eCTD is a fully specified standard.","test":"Build the minimum toolchain, use it for two real academic new-indication submissions to FDA and EMA, and publish the time and cost against a consultant-led equivalent.","maturity":"speculative","actor":"engineering","cost":"small","horizonYears":3},"route":"/ideas/idea-reg-open-source-dossier-tools/","neighbours":{"bottleneck":[{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}]}}